GERNEarnings•businesswire•
Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Sentiment:Negative (35)
Summary
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the second quarter of 2025 and recent business highlights. In a separate press release today, the Company announced the appointment of Harout Semerjian as incoming President and CEO. "We are pleased that our sharpened sales strategy is demonstrating signs of commercial success as e
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 6, 2025 by businesswire